Analysts Set Expectations for Avanos Medical Q3 Earnings

Avanos Medical, Inc. (NYSE:AVNS) – Equities research analysts at Zacks Research decreased their Q3 2025 earnings estimates for Avanos Medical in a research report issued on Wednesday, November 20th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.41 per share for the quarter, down from their prior forecast of $0.57. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical’s Q4 2025 earnings at $0.53 EPS and FY2025 earnings at $1.64 EPS.

Separately, StockNews.com cut Avanos Medical from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 3rd.

Avanos Medical Trading Up 4.1 %

NYSE AVNS opened at $19.37 on Monday. The firm’s 50 day moving average price is $21.73 and its two-hundred day moving average price is $21.56. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.46 and a current ratio of 2.22. Avanos Medical has a twelve month low of $17.39 and a twelve month high of $25.36. The stock has a market cap of $890.25 million, a price-to-earnings ratio of 56.97 and a beta of 0.92.

Hedge Funds Weigh In On Avanos Medical

Institutional investors and hedge funds have recently bought and sold shares of the business. State Board of Administration of Florida Retirement System boosted its holdings in shares of Avanos Medical by 8.6% during the first quarter. State Board of Administration of Florida Retirement System now owns 19,053 shares of the company’s stock worth $379,000 after purchasing an additional 1,516 shares during the period. Tidal Investments LLC acquired a new stake in shares of Avanos Medical during the 1st quarter valued at $439,000. Boston Partners purchased a new position in shares of Avanos Medical during the 1st quarter valued at $571,000. Azzad Asset Management Inc. ADV grew its holdings in shares of Avanos Medical by 8.5% during the 2nd quarter. Azzad Asset Management Inc. ADV now owns 28,521 shares of the company’s stock valued at $568,000 after acquiring an additional 2,223 shares in the last quarter. Finally, Natixis Advisors LLC increased its stake in shares of Avanos Medical by 19.5% in the second quarter. Natixis Advisors LLC now owns 18,878 shares of the company’s stock worth $376,000 after acquiring an additional 3,077 shares during the last quarter. Hedge funds and other institutional investors own 95.17% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.